Metin Kurtoglu, the Chief Technology Officer of $RNAC ($RNAC), sold 2,901 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.4%...
Cartesian Therapeutics details Phase 3 AURORA trial for Descartes-08, targeting myasthenia gravis with promising Phase 2b results.Quiver AI SummaryCartesian Therapeutics, Inc. announced that it is on track...
Metin Kurtoglu, the Chief Technology Officer of $RNAC ($RNAC), sold 32,789 shares of the company on 11-21-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Cartesian Therapeutics will present updated Phase 2b trial data for Descartes-08 at an upcoming cell therapy summit.Quiver AI SummaryCartesian Therapeutics, Inc. announced that it will present updated...